VSTM•benzinga•
Verastem Oncology's Phase 2 Dose Level 1 Shows 83% Overall Response Rate In Frontline Metastatic Pancreatic Ductal Adenocarcinoma
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2025 by benzinga